La cadena de opciones muestra datos clave de las opciones de acciones de MBX Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para MBX Biosciences..

MBX Biosciences (NASDAQ:MBX) Bolsa, Cadena de Opciones

MBX Biosciences

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

APLD

AZTR

CRKN

CVGW

GCTK

GLAC

HSDT

LFWD

MASS

ORKA

QBTS

QUBT

RIME

SGBX

VMAR

VRME

Descubre las acciones ganadoras y perdedoras en el premercado, con Vision Marine liderando un aumento del 45%.

Las acciones de Vision Marine (VMAR) se disparan un 45%; 20 acciones que se están moviendo en premercado

MBX Biosciences Inc

MICROBIX BIOSYSTEMS INC by Microbix Biosystems Inc.

Microbix Biosystems Inc

Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/TXN/earnings">closing bell on Tuesday, July 22.</a>
Analysts expect the Dallas, Texas-based company to report quarterly earnings at $1.33 per share, up from $1.22 per share in the year-ago period. Texas Instruments projects to report quarterly revenue at $4.32 billion, compared to $3.82 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 17, the company's board of directors declared a quarterly cash dividend of $1.36 per share of common stock.
Texas Instruments shares fell 1% to close at $214.57 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/txn/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>UBS analyst Timothy Arcuri maintained a Buy rating and raised the price target from $245 to $255 on July 14, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Mizuho analyst Vijay Rakesh maintained a Neutral rating and raised the price target from $170 to $205 on July 8, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Citigroup analyst Christopher Danely maintained a Buy rating and increased the price target from $220 to $260 on July 7, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Cantor Fitzgerald analyst Matthew Prisco maintained a Neutral rating and raised the price target from $170 to $200 on June 18, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Joseph Moore maintained an Underweight rating and increased the price target from $146 to $148 on April 24, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying TXN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/txn/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22035239/image-292-1024x579.png" alt="" class="wp-image-994841" style="width:663px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22035239/image-292-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22035239/image-292-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22035239/image-292-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22035239/image-292.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a></li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Analyst Ratings

TEXN

Texas Instruments Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

In a strategic move,&nbsp;Universal Music Group N.V.&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/UMGNF#OTC">UMGNF</a>), the world&#8217;s largest music label, has&nbsp;confidentially filed for a U.S.&nbsp;listing.
What Happened:&nbsp;UMG, which is primarily listed in the Netherlands, has initiated the process for a U.S. listing, as reported by&nbsp;Reuters. The company has not disclosed&nbsp;the size of the U.S.&nbsp;offering or the amount it intends to raise.
One of UMG's key shareholders, the Pershing Square fund headed by billionaire Bill Ackman, had earlier pushed for the company to go public in the United States.
UMG&#8217;s star-studded roster includes&nbsp;Taylor Swift,&nbsp;Billie Eilish,&nbsp;Drake,&nbsp;The Weeknd,&nbsp;Ariana Grande and&nbsp;Harry Styles.
More companies are seeking U.S. listings to take advantage of the strong rebound in American equity markets, after a temporary slowdown caused by uncertainty over President Donald Trump&#8216;s tariff policies.
Confidential filings allow companies to keep their financial and strategic details private while coordinating with regulators and assessing investor interest ahead of making the information public.
SEE ALSO:&nbsp;<a href="https://benzinga.com/crypto/cryptocurrency/25/07/46529190/trader-who-called-bitcoin-ethereum-solana-bottom-in-april-now-warns-local-top-likely-in-aug" target="_blank" rel="noreferrer noopener">Trader Who Called Bitcoin, Ethereum, Solana Bottom In April Now Warns Local Top Likely In August</a>
Why It Matters: This move comes after Bill Ackman, a non-Executive Director, <a href="https://www.benzinga.com/25/05/45401638/howard-hughes-rises-nearly-3-in-pre-market-as-bill-ackman-exits-from-universal-music-groups-board-to-prioritize-new-investments">stepped down </a>from the Board of Directors of Universal Music Group to focus on new obligations towards Howard Hughes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>).
Furthermore, the company&#8217;s decision to list in the U.S. could potentially boost its visibility and market presence, especially considering the recent success of its artists. For instance, Taylor Swift&#8217;s recent acquisition of her <a href="https://www.benzinga.com/news/entertainment/25/06/45783291/spotify-early-winner-from-taylor-swift-buying-back-old-albums-a-love-story-for-fans-streaming-company">old albums</a> led to a surge in streams of her old songs, benefiting streaming platforms like Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>).
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/sports/25/07/46439928/bill-ackman-pledges-10-million-gift-to-hall-of-fame-after-his-disastrous-professional-debut-and-will-manage-it-for-free">Bill Ackman Pledges $10 Million Gift To Hall Of Fame After His Disastrous Professional Debut — And Will Manage It For Free</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Entertainment

SPOT

UMGNF

Bill Ackman-Backed Universal Music Group Files For US Listing

Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/noc/earnings">opening bell on Tuesday, July 22.</a>
Analysts expect the Falls Church, Virginia-based company to report quarterly earnings at $6.68 per share, up from $6.36 per share in the year-ago period. Northrop Grumman projects to report quarterly revenue at $10.15 billion, compared to $10.22 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Northrop Grumman, in an exchange filing, said that on May 29, it had issued $1 billion in new senior notes, split evenly between two tranches maturing in 2030 and 2035.
Northrop Grumman shares fell 0.7% to close at $515.29 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/NOC/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Deutsche Bank analyst Scott Deuschle downgraded the stock from Buy to Hold and cut the price target from $580 to $542 on July 8, 2025. This analyst has an accuracy rate of 81%.</li>
<li>Wells Fargo analyst Matthew Akers maintained an Overweight rating and cut the price target from $547 to $525 on April 24, 2025. This analyst has an accuracy rate of 75%.</li>
<li>RBC Capital analyst Ken Herbert maintained an Outperform rating and slashed the price target from $575 to $550 on April 23, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Truist Securities analyst Michael Ciarmoli maintained a Buy rating and cut the price target from $600 to $550 on April 23, 2025. This analyst has an accuracy rate of 85%.</li>
<li>Susquehanna analyst Charles Minervino maintained a Positive rating and cut the price target from $557 to $540 on April 23, 2025. This analyst has an accuracy rate of 64%.</li>
</ul>
Considering buying NOC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22033905/image-291-1024x583.png" alt="" class="wp-image-994819" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22033905/image-291-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22033905/image-291-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22033905/image-291-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22033905/image-291.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a> </li>
</ul>
Photo via Shutterstock

Northrop Grumman Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Sasol Reports Improved Q4 FY25 Sales With Higher Liquid Fuels Volumes, Stronger External Gas Demand, And Increased Revenue In International Chemicals Despite Lower Year-on-Year Prices

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is back under the scrutiny of authorities as the California DMV, or Department of Motor Vehicles, filed a lawsuit to ban Tesla from selling cars in the state for 30 days over false advertising.
Check out the current price of <a href="https://benzinga.com/quote/tsla">TSLA stock here</a>.
What Happened: The DMV claims that Elon Musk's EV giant has misled consumers about the capabilities of Tesla's Autopilot and Full Self-Driving features, Electrek reported <a href="https://electrek.co/2025/07/21/tesla-tsla-might-lose-right-sell-cars-california-false-advertising-lawsuit/">on</a> Monday.
The DMV launched a probe into Tesla in 2021 for misleading advertising and officially sent in an inquiry to the company in 2022, asking Tesla to respond to "creating incorrect perceptions" about its systems, the report suggests.
However, Tesla states that the alerts in the FSD or Autopilot system, asking drivers to be attentive, should be enough to offset any misleading statements. A court has now scheduled a 5-day hearing and the DMV is pursuing a 30-day suspension of Tesla's dealer license in the state, the report says.
"The Department seeks an order suspending Respondent's manufacturer and dealer licenses for not less than thirty (30) days," the DMV appeal to the court states.
Why It Matters: Any suspension on Tesla's sales could prove to be detrimental for the company, which has experienced a <a href="https://www.benzinga.com/markets/tech/25/07/46436501/ev-prices-drop-2-8-in-june-as-incentives-surge-amid-tumbling-tesla-sales">12.6% decline in sales </a>in the U.S. during Q2, but remains a segment leader with 44% EV market share.
Tesla's sales, however, have experienced a rebound in China, where the company recorded over 12.3k insured registrations in July's second week. Tesla also filed for a long-range <a href="https://www.benzinga.com/markets/asia/25/07/46460445/elon-musk-led-tesla-files-for-model-3-trim-in-china-with-500-mile-range-amid-surge-in-sales-report">Model 3+ trim in China</a>, offering over 500 miles on a single charge.
The automaker also shared that it recorded over <a href="https://www.benzinga.com/markets/tech/25/07/46512836/elon-musks-tesla-announces-3-million-model-3-units-sold-worldwide">3 million Model 3 units</a> sold worldwide. This comes in after Tesla's Q2 <a href="https://www.benzinga.com/markets/tech/25/07/46239998/dan-ives-hails-teslas-better-than-expected-q2-deliveries-says-fireworks-come-early-for-elon-musk-led-ev-giant">deliveries fared better</a> than what was expected by experts.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="202" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031851/TSLA-JUL-22-2025-1-1-1024x202.jpg" alt="" class="wp-image-994790" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031851/TSLA-JUL-22-2025-1-1-1024x202.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031851/TSLA-JUL-22-2025-1-1-300x59.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031851/TSLA-JUL-22-2025-1-1-768x151.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031851/TSLA-JUL-22-2025-1-1-1536x303.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031851/TSLA-JUL-22-2025-1-1.jpg 1557w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Tesla offers Satisfactory Momentum and Quality, while scoring well on the Growth metric, but offering poor Value. For more such insights, sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46536517/bank-of-america-sees-11-upside-for-tesla-stock-despite-ev-credit-phase-out-tariff-risks-promise-to-deliver-unsupervised-fsd">Bank Of America Sees 11% Upside For Tesla Stock Despite EV Credit Phase-Out, Tariff Risks: &#8216;Promise To Deliver Unsupervised FSD&#8217;</a></li>
</ul>
Photo Courtesy: Ian Dewar Photography On Shutterstock.com

Tech

TSLA

Elon Musk's Tesla Could Lose License To Sell Cars In California Amid Autopilot, FSD False Advertising Lawsuit: Report

DVLT

Burke Products Selects Datavault AI To Deliver Advanced Data And Acoustic Technology Solutions Across National Defense Contracts

SHOT

Reported Earlier, Safety Shot Prices $10.6M Registered Direct Offering Of 28,648,648 Common Shares At $0.37 Per Share With Institutional Investor Participation

For the full year 2025, the Company expects:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Updated Guidance</td>
<td>Prior Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Full Year 2025 Guidance</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>ASM growth (YoY)</td>
<td>~7%</td>
<td>8% to 9%</td>
</tr>
<tr>
<td>EBITDAR margin</td>
<td>32% to 33%</td>
<td>-</td>
</tr>
<tr>
<td>CAPEX (1)</td>
<td>~$250 million</td>
<td>~$250 million</td>
</tr>
<tr>
<td>Average USD/MXN rate</td>
<td>~Ps. 19.65</td>
<td>-</td>
</tr>
<tr>
<td>Average U.S. Gulf Coast jet fuel price</td>
<td>~$2.10</td>
<td>-</td>
</tr>
<tr>
<td colspan="3">(1) CAPEX net of financed fleet predelivery payments.</td>
</tr>
</tbody>
</table>
</figure>
For the third quarter of 2025, the Company expects:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>3Q'25</td>
<td>3Q'24 (2)</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>3Q'25 Guidance</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>ASM growth (YoY)</td>
<td>~6%</td>
<td>-14.4%&nbsp;&nbsp;</td>
</tr>
<tr>
<td>TRASM</td>
<td>~$8.6 cents</td>
<td>$9.38 cents</td>
</tr>
<tr>
<td>CASM ex fuel</td>
<td>~$5.5 cents</td>
<td>$5.39 cents</td>
</tr>
<tr>
<td>EBITDAR margin</td>
<td>32% to 33%</td>
<td>38.7%</td>
</tr>
<tr>
<td>Average USD/MXN rate</td>
<td>~Ps. 19.00</td>
<td>Ps. 18.92</td>
</tr>
<tr>
<td>Average U.S. Gulf Coast jet fuel price</td>
<td>~$2.20</td>
<td>$2.24</td>
</tr>
<tr>
<td colspan="3">(2) For convenience purposes, actual reported figures for 3Q'24 are included.</td>
</tr>
</tbody>
</table>
</figure>
The full year and third quarter 2025 outlooks presented above include the compensation that Volaris expects to receive for the projected grounded aircraft resulting from the GTF engine inspections, in accordance with the Company's agreement with Pratt &amp; Whitney.
The Company's outlook is subject to unforeseen disruptions, macroeconomic factors, or other negative impacts that may affect its business and is based on several assumptions, including the foregoing, which are subject to change and may be outside the control of the Company and its management. The Company's expectations may change if actual results vary from these assumptions. There can be no assurances that Volaris will achieve these results.

Guidance

VLRS

Reported Earlier, Volaris Lowers Full-Year 2025 ASM Growth Forecast to ~7%, Maintains $250M Capex And 32%–33% EBITDAR Margin Outlook; Q3 Guidance Sees ~6% ASM Growth, $8.6 Cents TRASM, and $5.5 Cents CASM ex-Fuel Amid Continued GTF Compensation Impact

Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) will release earnings results for the second quarter before the <a href="https://www.benzinga.com/quote/PM/earnings">opening bell on Tuesday, July 22.</a>
Analysts expect the Stamford, Connecticut-based company to report quarterly earnings at $1.86 per share, up from $1.59 per share in the year-ago period. Philip Morris is projected to report quarterly revenue of $10.33 billion, compared to $9.47 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On June 13, Philip Morris International declared a regular quarterly dividend of $1.35 per share.
Philip Morris shares gained 1% to close at $180.48 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Citigroup analyst Simon Hales maintained a Buy rating and raised the price target from $188 to $200 on July 10, 2025. This analyst has an accuracy rate of 60%.</li>
<li>JP Morgan analyst Jared Dinges maintained an Overweight rating and raised the price target from $175 to $190 on July 10, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Barclays analyst Gaurav Jain maintained an Overweight rating and increased the price target from $220 to $225 on July 10, 2025. This analyst has an accuracy rate of 66%.</li>
<li>B of A Securities analyst Lisa Lewandowski maintained a Buy rating and raised the price target from $182 to $200 on June 4, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Matthew Smith maintained a Buy rating and increased the price target from $168 to $186 on April 24, 2025. This analyst has an accuracy rate of 60%</li>
</ul>
Considering buying PM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PM/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22032524/image-290-1024x590.png" alt="" class="wp-image-994801" style="width:569px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22032524/image-290-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22032524/image-290-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22032524/image-290-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22032524/image-290.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a></li>
</ul>
Photo via Shutterstock

Top Wall Street Forecasters Revamp Philip Morris Expectations Ahead Of Q2 Earnings

Former&nbsp;Federal Reserve&nbsp;Chairs&nbsp;Ben Bernanke&nbsp;and&nbsp;Janet Yellen&nbsp;have cautioned that President&nbsp;Donald Trump&#8216;s ongoing pressure on the current Fed chief,&nbsp;Jerome Powell, could have dire long-term consequences for the U.S. economy.
What Happened: Bernanke and Yellen, in an op-ed published by&nbsp;<a href="https://www.nytimes.com/2025/07/21/opinion/federal-reserve-independence-trump.html">The New York Times</a>&nbsp;on Monday, emphasized the importance of maintaining the central bank&#8217;s independence. They urged Trump to select a successor for Powell who would continue to uphold this independence.
The ex-Fed chairs stated, &#8220;President&nbsp;Trump, like all Americans, is&nbsp;entitled to express his views&nbsp;on monetary policy. He will&nbsp;have a chance to put&nbsp;his stamp on the Federal&nbsp;Reserve by nominating someone to&nbsp;succeed Mr. Powell when his&nbsp;term ends next spring.&#8221;
They further advised Trump to nominate a candidate who would &#8220;keep an appropriate distance between&nbsp;the Fed and short-term politics,&#8221; and&nbsp;is committed to preserving the&nbsp;Fed&#8217;s&nbsp;independence in monetary policy decision&nbsp;making.
Citing past instances, Bernanke and Yellen cautioned that if the Fed&#8217;s decisions are swayed by political pressure rather than data, it could result in &#8220;inevitably higher inflation and economic damage.&#8221; They noted that such actions could erode public confidence, leading to higher&nbsp;borrowing costs for everyone, including&nbsp;home buyers, businesses, and the government.
SEE ALSO:&nbsp;<a href="https://benzinga.com/crypto/cryptocurrency/25/07/46521555/shiba-inu-surges-37-in-1-month-how-high-can-the-shib-price-go" target="_blank" rel="noreferrer noopener">Shiba Inu Surges 37% In 1 Month: How High Can The SHIB Price Go? &#8211; Benzinga</a>
Why It Matters: Federal Reserve Chair Jerome Powell's second term ends in May, and Trump has expressed interest in replacing him. Despite the legal and market-related risks of doing so, Trump is expected to nominate someone more aligned with his policy goals.
This op-ed comes amid a series of criticisms and warnings from financial experts and former government officials about Trump&#8217;s economic policies.
Janet Yellen, who served as the Fed Chair under former President Barack Obama, has been a vocal critic of Trump&#8217;s economic policies. In a recent interview with <a href="https://www.benzinga.com/markets/25/04/44760306/former-treasury-secretary-janet-yellen-says-trump-has-taken-a-wrecking-ball-to-the-economy-couldnt-think-of-a-more-devastating-economic-agenda">CNN</a>, she described Trump&#8217;s policies as the &#8220;worst self-inflicted wound&#8221; on a well-functioning economy.
Meanwhile, economist&nbsp;Peter Schiff&nbsp;has accused Trump of&nbsp;<a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46512725/peter-schiff-says-trump-wants-fed-chair-jerome-powell-to-do-exactly-what-he-accused-janet-yellen-of-doing-for-obama-a-dangerous-step">hypocrisy</a>&nbsp;regarding the Federal Reserve&#8217;s interest rate policy, stating that Trump&#8217;s demands mirror what he had previously condemned.
Another former Trump advisor, economist&nbsp;Judy Shelton, has also criticized the Federal Reserve, calling for a&nbsp;<a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46535742/ex-trump-advisor-judy-shelton-slams-federal-reserves-900-billion-losses-says-violates-the-norms-to-have-a-fed-chair-who-cant-be-fired">structural overhaul</a>&nbsp;and questioning the notion of central bank independence.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46512871/trump-says-he-doesnt-need-scott-bessents-advice-to-fire-jerome-powell-i-know-better-than-anybody-whats-good-for-the-market">Trump Says He Doesn&#8217;t Need Scott Bessent&#8217;s Advice To Fire Jerome Powell: &#8216;I Know Better Than Anybody What&#8217;s Good For The Market&#8217; </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

Former Fed Chairs Ben Bernanke, Janet Yellen Warn Trump's Pressure On Powell Could Lead To 'Inevitably Higher Inflation And Economic Damage'

Renowned TV host Jim Cramer has suggested that Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) could be in for a significant revaluation, akin to that of Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>).
What Happened: CNBC&#8217;s Mad Money host Cramer has expressed his belief that Cisco could be in for a substantial revaluation, similar to that of Oracle, as <a href="https://www.insidermonkey.com/blog/cisco-systems-inc-csco-it-could-have-an-oracle-like-revaluation-says-jim-cramer-1572097/#google_vignette">reported</a> by Insider Monkey.
This prediction is based on the company&#8217;s strong performance and its strategic positioning in the AI and cybersecurity sectors.
Cisco has seen a 15.63% increase in its share price this year, largely due to its impressive financial results, including a significant revenue and EPS beat in May.
Cramer has previously highlighted the company&#8217;s potential as the backbone of AI, and in his recent remarks, he emphasized the company&#8217;s role in connecting data centers to other systems.
See Also: <a href="https://benzinga.com/crypto/cryptocurrency/25/07/46511527/bitcoin-flat-as-1-billion-whale-move-sparks-speculation-ethereum-dogecoin-spike-analyst-says-btcs-next-leg-up-will-pump-it-above-130000" target="_blank" rel="noopener">Bitcoin Flat As $1 Billion Whale Move Sparks Speculation, Ethereum, Dogecoin Spike: Analyst Says BTC&#8217;s Next Leg Up Will Pump It Above $130,000 &#8211; Grayscale Bitcoin Mini Trust (BTC) Common units of frac</a>
Despite acknowledging Cisco&#8217;s potential as an investment, Cramer believes that other AI stocks may offer greater returns with less downside risk.
Why It Matters: This news comes on the heels of a recent report that highlighted Cisco&#8217;s quiet success in the AI sector. The company&#8217;s <a href="https://www.benzinga.com/markets/tech/25/07/46442422/cisco-is-quietly-beating-the-ai-hype-should-investors-pay-closer-attention">stock has risen by approximately</a> 10.89% in the last six months.
In May, Cisco reported <a href="https://www.benzinga.com/news/earnings/25/05/45422303/cisco-shares-climb-after-q3-eps-revenue-beat-estimates-details">quarterly earnings of $0.96 per share</a>, surpassing the analyst consensus estimate of $0.92. Revenue for the quarter reached $14.15 billion, topping Wall Street&#8217;s projection of $14.08 billion and marking an increase from $12.70 billion in the same quarter last year.
Furthermore, <a href="https://www.benzinga.com/markets/tech/25/07/46410415/oracle-to-invest-3-billion-in-ai-and-cloud-infrastructure-expansion-across-germany-netherlands">Oracle&#8217;s recent announcement</a> of a $3 billion investment in AI and cloud infrastructure expansion across Europe also underscores the growing importance of AI in the tech industry.
Price Action: Oracle closed Monday at $234.54, down 0.78%, and slipped another 2.01% in after-hours trading. Meanwhile, Cisco ended the day at $68.34, gaining 0.43% during regular hours and edging up an additional 0.21% after hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://benzinga.com/news/politics/25/07/46511833/tim-burchett-shrugs-off-trumps-stupid-remark-doubles-down-on-jeffrey-epstein-files-push-doesnt-give-up-its-secrets-very-easy" target="_blank" rel="noopener">Tim Burchett Shrugs Off Trump&#8217;s &#8216;Stupid&#8217; Remark, Doubles Down On Jeffrey Epstein Files Push: &#8216;Doesn&#8217;t Give Up Its Secrets Very Easily&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: MacroEcon/Shutterstock

CSCO

ORCL

Could Cisco Be The Next Oracle? Jim Cramer Says AI, Cybersecurity Make CSCO A Sleeper Stock Set For Big Revaluation

General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) will release earnings results for the second quarter before the <a href="https://www.benzinga.com/quote/GM/earnings">opening bell on Tuesday, July 22.</a>
Analysts expect the Detroit, Michigan-based company to report quarterly earnings at $2.48 per share, down from $3.06 per share in the year-ago period. General Motors is projected to report quarterly revenue of $46 billion, compared to $47.97 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The company has beaten analyst estimates for revenue in 12 straight quarters.
General Motors shares fell 0.02% to close at $53.21 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/gm/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Piper Sandler analyst Alexander Potter maintained a Neutral rating and raised the price target from $43 to $48 on May 22, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Mizuho analyst Vijay Rakesh maintained an Outperform rating and raised the price target from $53 to $58 on May 16, 2025. This analyst has an accuracy rate of 78%.</li>
<li>RBC Capital analyst Tom Narayan maintained an Outperform rating and increased the price target from $55 to $57 on May 2, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Citigroup analyst Michael Ward initiated coverage on the stock with a Buy rating and a price target of $62 on April 23, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Goldman Sachs analyst Mark Delaney maintained a Buy rating and slashed the price target from $73 to $63 on April 10, 2025. This analyst has an accuracy rate of 77%</li>
</ul>
Considering buying GM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/GM/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="567" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031544/image-289-1024x567.png" alt="" class="wp-image-994784" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031544/image-289-1024x567.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031544/image-289-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031544/image-289-768x425.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22031544/image-289.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a></li>
</ul>
Photo via Shutterstock

General Motors Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

President Donald Trump threatened Sunday to torpedo Washington's planned RFK Stadium redevelopment unless the NFL franchise now called the Commanders revives its former Redskins nickname.
What Happened: In a two‑part Truth Social salvo, Trump first <a href="https://x.com/TrumpTruthOnX/status/1947018752618594581">wrote</a>, "My statement on the Washington Reskins has totally blown up, but only in a very positive way." He continued: "I may put a restriction on them that if they don't change the name back to the original ‘Washington Redskins,' and get rid of the ridiculous moniker, ‘Washington Commanders,' I won't make a deal for them to build a Stadium in Washington."
Minutes earlier, he had demanded faster action, <a href="https://x.com/TrumpTruthOnX/status/1946939500346900737">posting</a>, "The Washington ‘Whatever's' should IMMEDIATELY change their name back to the Washington Redskins Football Team." The outburst marks Trump's most explicit attempt to leverage federal influence over the 173‑acre RFK site, whose control Congress transferred to the District of Columbia in January.
District officials and owner Josh Harris announced in April a tentative agreement to return the club to the capital in 2030, replacing its suburban Maryland venue, according to Reuters. The deal still needs D.C. Council approval, and Trump's post suggested he could try to intervene through remaining federal oversight of the property.
See Also: <a href="https://www.benzinga.com/crypto/25/07/46536745/jamie-dimon-trying-to-undermine-trumps-plans-to-make-us-crypto-capital-of-the-world-says-tyler-winklevoss">Jamie Dimon Trying To Undermine Trump&#8217;s Plans To Make US Crypto Capital Of The World, Says Tyler Winklevoss</a>
Trump coupled his NFL threat with a swipe at Major League Baseball, urging the Cleveland Guardians to reclaim the Indians&#8217; identity and insisting owner Matt Dolan "lost three Elections in a row because of that ridiculous name change."
Why It Matters: Trump&#8217;s stadium veto threat carries little legal weight because land‑use authority now rests with the district, not the White House, states Reuters.
Congress retains power over D.C.'s budget, but legal scholars say any presidential attempt to halt a local lease could trigger a court fight with bipartisan lawmakers who backed the transfer. It is worth noting that it was Joe Biden who signed into law a bill that transfers the land that includes the old RFK Stadium from the federal government to city control in January, as per an Associated Press <a href="https://apnews.com/article/washington-commanders-rfk-stadium-5bf177d95eb5bb1188858f366292ed4e">report</a>.
For now, the posts have roiled a franchise already navigating a $3.7 billion financing debate and revived a mascot battle many fans and Native American leaders hoped was settled three years ago.
Photo Courtesy: kovop on Shutterstock.com
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46536548/hunter-biden-blames-father-joes-re-election-loss-on-democrats-that-chose-not-to-remain-loyal-rejects-health-cover-up-suggestions">Hunter Biden Blames Father Joe&#8217;s Re-Election Loss On Democrats That Chose Not To &#8216;Remain Loyal,&#8217; Rejects Health Cover Up Suggestions</a></li>
</ul>

Politics

Trump Demands Washington Commanders 'Immediately' Return To Previous Name Or He'll Sink RFK Stadium Deal

Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.73) by 26.03 percent. This is a 700 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $693.00 million which beat the analyst consensus estimate of $671.07 million by 3.27 percent. This is a 4.55 percent decrease over sales of $726.00 million the same period last year.

Controladora Vuela Q2 EPADS $(0.54) Beats $(0.73) Estimate, Sales $693.00M Beat $671.07M Estimate

<ul>
<li>Commercial Aviation reported an 8-year backlog record of US$13.1 billion and the division book-to-bill reached 1.8x over the past 12 months,</li>
<li>The E175 celebrated an important milestone – 1,000 units sold since its 2005 launch;</li>
<li>Executive Aviation delivered 38 aircraft during the quarter, up 41% year-over-year;</li>
<li>The backlog for Defense &amp; Security reached US$4.3 billion, 2x higher than last year;</li>
<li>Services &amp; Support registered a new backlog record, up 55% year-over-year.</li>
</ul>

Embraer-Empresa Brasileira De Aeronautica

Reported Earlier, Embraer Posts 30% Rise In Aircraft Deliveries And 40% Year-Over-Year Backlog Surge Across All Business Units For Q2

<ul>
<li>Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care</li>
<li>Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice</li>
</ul>

BIIB

Reported Earlier, Biogen To Present 48-Month LEQEMBI Clarity AD Data And Subcutaneous Dosing Insights At Alzheimer's Association International Conference 2025

SRPT

Reported Earlier, Sarepta Therapeutics Voluntarily Pauses ELEVIDYS Shipments In The US To Complete FDA Safety Labeling Supplement Process

Cementos Pacasmayo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAC#NYSE">CPAC</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.10 by 56 percent. This is a 30 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $137.00 million which beat the analyst consensus estimate of $123.20 million by 11.20 percent. This is a 12.17 percent increase over sales of $122.13 million the same period last year.

Earnings Beats

CPAC

Cementos Pacasmayo Q2 EPS $0.16 Beats $0.10 Estimate, Sales $137.00M Beat $123.20M Estimate

Elon Musk has hailed Neuralink as the billionaire's Brain-Chip Interface company successfully conducted its latest implant trial, taking the total number of Neuralink implant recipients to 9 patients.
What Happened: The billionaire took to social media platform X to hail the feat accomplished by Neuralink on Monday as he quoted a post from the company. Musk said that the company will do "life(live)-changing good" for "billions of people" through its work on the BCI implants.
"Imagine your loved one being able to walk again or your parent with dementia being able to recognize their child again," Musk added in the post.
Neuralink had said in the original post that the company had successfully conducted trials on Patients 8 and 9, adding that this was the first time Neuralink had accomplished two surgeries in a single day.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Neuralink will do live-changing good for ultimately millions, maybe billions, of people. Imagine your loved one being able to walk again or your parent with dementia being able to recognize their child again. <a href="https://t.co/I59yohrJ0e">https://t.co/I59yohrJ0e</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1947346507927326761?ref_src=twsrc%5Etfw">July 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Neuralink's co-founder DJ SEO also took to X on Monday to share that the company has set a target of conducting over 20 BCI implant trials before the end of the year.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Our goal is at least 20 before the end of 2025 <a href="https://t.co/eSrPexTxdF">https://t.co/eSrPexTxdF</a> <a href="https://t.co/cI8imxuy3s">pic.twitter.com/cI8imxuy3s</a>
&mdash; DJ Seo (@djseo) <a href="https://twitter.com/djseo/status/1947343233492701396?ref_src=twsrc%5Etfw">July 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The news comes as Neuralink secured over <a href="https://www.benzinga.com/general/health-care/25/05/45634160/elon-musks-neuralink-hits-9-billion-valuation-with-new-funding">$650 million in Series E funding</a>, with investors including the likes of Cathie Wood's ARK Invest, fetching a valuation of over $9 billion.
Musk had also said that Neuralink plans to conduct trials of its <a href="https://www.benzinga.com/markets/tech/25/06/46020319/elon-musk-says-neuralinks-blindsight-implant-will-help-people-see-radar-infrared-like-a-superpower-ahead-of-human-trial-next-year">vision-restoring implant</a>, Blindsight, which could help completely blind people see again, in the UAE by 2026.
However, Musk's company has also been on the <a href="https://www.benzinga.com/news/health-care/25/06/46160805/elon-musk-says-clear-path-to-restoring-hearing-with-neuralink-but-the-deaf-community-want-to-have-their-say">receiving end of criticism</a> from the deaf community following the billionaire's claims that Neuralink would help restore hearing.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46536292/trumps-new-zev-credit-regulations-arent-as-bad-for-elon-musk-says-piper-sandler-tesla-will-still-book-around-3-billion">Trump&#8217;s New ZEV Credit Regulations Aren&#8217;t &#8216;As Bad&#8217; For Elon Musk, Says Piper Sandler: &#8216;Tesla Will Still Book Around $3 Billion…&#8217;</a></li>
</ul>
Photo courtesy: rafapress / Shutterstock.com

Elon Musk Says Neuralink Will Do 'Life-Changing' Good For Billions As Company Successfully Adds 9 BCI Implants, Targets 20 By End Of 2025

The collaborative design software start-up Figma is eyeing a valuation of $13.6 billion on its market debut; however, experts predict that its valuation could stretch up to $16 billion including restricted stock units and options.
What Happened: The firm seeks to raise approximately $1.03 billion through its initial public offering, which could value it at $13.6 billion by selling nearly 37 million shares priced between $25 and $28 each.
This announcement comes as the company stated on its <a href="https://www.figma.com/blog/ipo-roadshow-launch/">website</a> on Monday that the proposed offering consists of 12,472,657 shares of Class A common stock being offered by Figma and 24,646,423 shares of Class A common stock being offered by certain of Figma's existing stockholders. 
While this approximately comes up to 37 million shares, Bloomberg&#8217;s equities capital markets reporter Anthony Hughes said that &#8220;I think it&#8217;s interesting because once you add in restricted stock units and options, you know, equivalent of options, and they&#8217;re like, the evaluation will be a bit higher than, more like $16 billion, $16.5 billion.&#8221;
According to him, the deal is going to be priced next week, on Wednesday, July 30.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Figma, along with some of its investors, are seeking to raise as much as $1.03 billion in a US initial public offering, which could give it a market value of as much as $13.6 billion. Anthony Hughes reports <a href="https://t.co/77LpqNvBrg">https://t.co/77LpqNvBrg</a> <a href="https://t.co/mucR492xz3">pic.twitter.com/mucR492xz3</a>
&mdash; Bloomberg TV (@BloombergTV) <a href="https://twitter.com/BloombergTV/status/1947307443911872711?ref_src=twsrc%5Etfw">July 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The company is known for its collaborative browser-based tools, which are used by <a href="https://www.benzinga.com/markets/ipos/25/07/46212893/figma-targets-wall-street-debut-after-20-billion-adobe-deal-collapse">major clients</a> such as Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>).
As of March 31, the company had invested approximately $70 million in Bitwise Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITB#NYSE">BITB</a>) and plans to invest an additional $30 million in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), according to its filing.
See Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/07/46515755/3-stocks-with-sky-high-overbought-signals-quantumscape-opendoor-cogent-flash-rsi-red-flags">3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags</a>
Why It Matters: This valuation of approximately $16 billion is a step down from the $20 billion valuation Figma would have achieved in its proposed sale to Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>), which was abandoned <a href="https://www.benzinga.com/news/large-cap/23/07/33353200/adobes-game-changing-20-billion-figma-acquisition-under-global-regulatory-microscope">due to regulatory hurdles</a>. 
Figma&#8217;s platform is utilized by <a href="https://www.benzinga.com/markets/ipos/25/07/46212893/figma-targets-wall-street-debut-after-20-billion-adobe-deal-collapse">95% of the Fortune 500</a> and 78% of the Forbes Global 2000, demonstrating its extensive use across various sectors.
The company has significantly broadened its offerings, introducing features like Dev Mode for developers, FigJam for brainstorming, and innovative AI-driven tools such as Figma Make, which can create working prototypes based on user prompts.
Its business model is subscription-based, offering tiered plans for individuals, organizations, and enterprises, with pricing tailored to different user roles and workflows.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended higher on Monday. The SPY was up 0.19% at $628.77, while the QQQ advanced 0.52% to $564.17, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Monday, the futures of the S&amp;P 500, Nasdaq 100, and Dow Jones indices were mixed.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46463595/dan-ives-picks-5-stocks-for-2nd-half-of-2025-nvidia-palantir-microsoft-and-more-golden-age-of-tech-is-here-with-ai-revolution">Dan Ives Picks 5 Stocks For 2nd Half Of 2025: Nvidia, Palantir, Microsoft And More: &#8216;Golden Age Of Tech Is Here With AI Revolution&#8217;</a></li>
</ul>
Photo courtesy: M.oo / Shutterstock.com

IPOs

$BTC

ADBE

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

GOOG

GOOGL

MSFT

Figma's Market Debut Could Value Design Giant At $16 Billion, Down From Adobe's $20 Billion Deal

Press Releases

MBX Biosciences Announces Additions to Leadership Team

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Management

MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Health Care

MBX Biosciences to Participate in June Investor Conferences

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

General

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Comments

MBX Biosciences

MBX Biosciences (MBX) Opciones

MBX Biosciences (NASDAQ:MBX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL